Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers.

The pharmacokinetics and pharmacodynamics of recombinant human interferon-beta (rHuIFN-beta 1a) were assessed following administration to 12 healthy male volunteers. Each subject received, in a double-blind, balanced, random-order, crossover sequence, single doses of 6 MIU of rHuIFN-beta 1a (Rebif) i.v., i.m., and s.c. or matching placebo on four occasions separated by washout periods of 1 week. Blood samples were collected at preset times for the measurement of serum IFN-beta levels and of intracellular 2'-5'-oligoadenylate synthetase levels. Blood pressure, sitting heart rate, respiratory rate, oral body temperature, and tolerance were monitored regularly. All administrations of rHuIFN-beta 1a were well tolerated, although about half of the subjects had a flu-like syndrome, as expected. After i.v. bolus injection, the pharmacokinetics of rHuIFN-beta 1a were well described by a classic two-compartment model. Mean total clearance of rHuIFN-beta 1a was about 100 L.h-1. The distribution half-life was 5 min, and the terminal half-life was approximately 5 h. After i.m. or s.c. injection, serum IFN-beta profiles were rather flat, and about one sixth of the administered dose was available systemically. Extent and duration of clinical and biologic effects were independent of the route of administration and of the IFN-beta serum levels. Biologic pharmacodynamic effects persisted even when IFN-beta serum levels had returned to baseline and were still significantly elevated 3 days after a single dose. Because of the independence of the extent and duration of clinical and biologic pharmacodynamic effects from the route of administration and from the IFN-beta serum levels, the s.c route of administration is preferred in indications in which primarily an immunomodulatory action is sought. Predominantly antiviral and antiproliferative activity is enhanced by the i.v. route to provide adequate drug levels at the site of pathology, although its application is limited on practical grounds.

[1]  S. Astolfi,et al.  Double-Blind Randomized Phase I Study on the Clinical Tolerance and Pharmacodynamics of Natural and Recombinant Interferon-β Given Intravenously , 1994 .

[2]  B. Storer,et al.  Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-beta. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[3]  S. McDonald,et al.  Combined Betaseron R (recombinant human interferon beta) and radiation for inoperable non-small cell lung cancer. , 1993, International journal of radiation oncology, biology, physics.

[4]  S. Astolfi,et al.  Double-Blind Randomized Phase I Study on the Clinical Tolerance and Biological Effects of Natural and Recombinant Interferon-β , 1992 .

[5]  B. Storer,et al.  Biological and Clinical Effects of the Combination of β- and γ-Interferons Administered as a 5-Day Continuous Infusion , 1990 .

[6]  M. Lindstrom,et al.  Basal and interferon-induced 2',5'-oligoadenylate synthetase in human monocytes, lymphocytes, and peritoneal macrophages. , 1990, Journal of interferon research.

[7]  B. Storer,et al.  Biological and Clinical Effects of Interferon-βser at Two Doses , 1990 .

[8]  B. Storer,et al.  Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine. , 1989, Journal of the National Cancer Institute.

[9]  A. Liberati,et al.  Biochemical Host Response to Interferon-β , 1988 .

[10]  A. Valéri,et al.  The lymphatic route. V. Distribution of human natural interferon-beta in rabbit plasma and lymph. , 1988, Journal of interferon research.

[11]  E. Borden,et al.  Clinical and biological effects of recombinant interferon-beta administered intravenously daily in phase I trial. , 1988, Journal of interferon research.

[12]  R. L. Jordan,et al.  Enhancement of monocyte class I and II histocompatibility antigen expression in man by in vivo beta-interferon. , 1987, Clinical and experimental immunology.

[13]  K C Zoon,et al.  Interferons and their actions. , 1987, Annual review of biochemistry.

[14]  M. Revel,et al.  Interferon-activated genes , 1986 .

[15]  D. Wallach,et al.  INTRAMUSCULAR HUMAN INTERFERON-β INJECTIONS IN TREATMENT OF CONDYLOMATA ACUMINATA , 1984, The Lancet.